Literature DB >> 33385294

Characteristics and predictors of post-transplant-associated hemophagocytic lymphohistiocytosis in adults.

Norimichi Hattori1, Misuzu Sato2, Yuka Uesugi3, Ayaka Nakata3, Yohei Sasaki3, Shotaro Shimada3, Megumi Watanuki3, Shun Fujiwara3, Yukiko Kawaguchi3, Nana Arai3, Yui Uto3, Tomoharu Matsui3, Kouji Yanagisawa3, Sachiko Tahara2, H Phillip Koeffler4, Keiichi Iezumi2, Tsuyoshi Nakamaki3.   

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is an uncontrolled hyperinflammatory disorder driven by an overactive immune system that results in high mortality. Post-transplant-associated hemophagocytic lymphohistiocytosis (PT-HLH) is a type of secondary HLH that occurs following allogeneic hematopoietic stem cell transplantation (allo-HSCT). The clinical features of PT-HLH remain unclear and diagnostic and prognostic tools have not yet been established. Here, we retrospectively evaluated the clinical manifestations and outcomes of PT-HLH in 94 patients who underwent allo-HSCT. According to our PT-HLH criteria (hyperferritinemia and increased macrophage count in bone marrow), PT-HLH occurred in 12 patients (12.8%). The PT-HLH patients showed splenomegaly (P = .001), a higher risk of engraftment failure (P = .013), and an increased percentage of macrophages and hemophagocytes in bone marrow aspirates (P = .0009 and P = .0006, respectively). Moreover, univariate and multivariate analyses revealed that the survival rate was lower in PT-HLH patients than non-PT-HLH patients (P = .0017 and P = .034, respectively). This study defines the clinical features of PT-HLH and PT-HLH criteria that could be useful tools for diagnosing PT-HLH.

Entities:  

Keywords:  Allogeneic hematopoietic stem cell transplantation; Hemophagocytic lymphohistiocytosis; Hemophagocytosis; Hyperferritinemia; Post-transplant-associated hemophagocytic lymphohistiocytosis

Year:  2021        PMID: 33385294     DOI: 10.1007/s12185-020-03067-6

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  3 in total

1.  Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society.

Authors:  J I Henter; G Elinder; A Ost
Journal:  Semin Oncol       Date:  1991-02       Impact factor: 4.929

2.  Ruxolitinib for hematopoietic cell transplantation-associated hemophagocytic lymphohistiocytosis.

Authors:  Rintaro Ono; Miho Ashiarai; Shinsuke Hirabayashi; Kazuyoshi Mizuki; Yosuke Hosoya; Hiroki Yoshihara; Junya Ohtake; Shinichiro Mori; Atsushi Manabe; Daisuke Hasegawa
Journal:  Int J Hematol       Date:  2020-09-26       Impact factor: 2.490

3.  An increase in MYC copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens.

Authors:  Francesca Schieppati; Piera Balzarini; Simona Fisogni; Alessandro Re; Chiara Pagani; Nicola Bianchetti; Lorenzo Micheli; Angela Passi; Samantha Ferrari; Adriana Maifredi; Chiara Bottelli; Rossella Leopaldo; Vilma Pellegrini; Fabio Facchetti; Giuseppe Rossi; Alessandra Tucci
Journal:  Haematologica       Date:  2019-08-08       Impact factor: 9.941

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.